IDO2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4587567	0.60	14/20
SCHEMBL4593874	0.67	13/20
Tryptanthrin (SCHEMBL2426211)	1.00	12/20
SCHEMBL4585634	0.80	12/20
SCHEMBL4585269	0.67	12/20
SCHEMBL4585174	0.65	12/20
SCHEMBL4585230	0.83	11/20
SCHEMBL4594184	0.69	11/20
SCHEMBL4586093	0.67	11/20
SCHEMBL4586132	0.67	11/20
SCHEMBL4593804	0.62	11/20
SCHEMBL4586274	0.71	10/20
SCHEMBL4585650	0.67	10/20
SCHEMBL4593605	0.61	10/20
SCHEMBL4585259	0.54	10/20
SCHEMBL4593229	0.49	10/20
SCHEMBL4586352	0.47	10/20
SCHEMBL4593709	0.67	9/20
SCHEMBL4585623	0.63	9/20
SCHEMBL4586346	0.49	9/20

Clinical trials — most relevant to IDO2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma	PHASE2	UNKNOWN
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma	PHASE1/PHASE2	COMPLETED
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	PHASE2	COMPLETED
Pembrolizumab in Treating Patients With Malignant Mesothelioma	PHASE2	COMPLETED
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer	PHASE2	UNKNOWN
A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma	PHASE2	WITHDRAWN
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck	PHASE2	ACTIVE_NOT_RECRUITING
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer	PHASE2	COMPLETED
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy	PHASE2	WITHDRAWN
Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.	PHASE1/PHASE2	UNKNOWN
CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients	PHASE2	UNKNOWN
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	PHASE2	COMPLETED
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.	PHASE1	COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients	PHASE1	COMPLETED
FS2 Safety and Tolerability Study in Healthy Volunteers	PHASE1	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	nan	COMPLETED
The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty	nan	UNKNOWN
A Longitudinal Study of Inflammatory Pathways in Depression	nan	COMPLETED
Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study	nan	COMPLETED
Effect of Genetic Alterations Affecting the Genes Encoding the Major Enzymes of the Kynurenine Pathway on Suicidal Behavior	nan	COMPLETED
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients	nan	RECRUITING
The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation	nan	COMPLETED
Role of Inflammation in Psychiatric Disorders in Patients With Cutaneous Lupus	nan	COMPLETED
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Fiber Metabolism in Chronic Obstructive Pulmonary Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a IDO2 binder may also engage these)

Protein	Name	Similarity
F1LV46	—	1.000	F1LV46 →
Q8R0V5	—	1.000	Q8R0V5 →
Q9ERD9	—	0.977	Q9ERD9 →
IDO1	Indoleamine 2,3-dioxygenase 1	0.977	landscape →
O70576	—	0.972	O70576 →
Q7Z3D6	—	0.971	Q7Z3D6 →
Q8BKF1	—	0.970	Q8BKF1 →
Q9UJ98	—	0.970	Q9UJ98 →
Q8K2Z4	—	0.970	Q8K2Z4 →
Q9DC40	—	0.970	Q9DC40 →
PARP3	Protein mono-ADP-ribosyltransferase PARP3	0.970	landscape →
Q99M76	—	0.969	Q99M76 →
Q8QZW3	—	0.968	Q8QZW3 →
Q91WR3	—	0.968	Q91WR3 →
P12530	—	0.968	P12530 →
D3ZND0	—	0.968	D3ZND0 →
MYBBP1A	Myb-binding protein 1A	0.968	landscape →
B4DZS4	—	0.968	B4DZS4 →
D3ZKX9	—	0.967	D3ZKX9 →
Q4R5Q4	—	0.967	Q4R5Q4 →
Q8VDP3	—	0.967	Q8VDP3 →
Q09M05	—	0.967	Q09M05 →
P10937	—	0.967	P10937 →
Q9UNS1	—	0.967	Q9UNS1 →
Q9UJY4	—	0.966	Q9UJY4 →
Q924T7	—	0.966	Q924T7 →
Q8BIR2	—	0.966	Q8BIR2 →
Q86VS3	—	0.966	Q86VS3 →
Q9D479	—	0.966	Q9D479 →
POLRMT	DNA-directed RNA polymerase, mitochondrial	0.966	landscape →